Relationships between diabetes and cognitive impairment

Endocrinology and Metabolism Clinics of North America

Volumn 43, Issue 1, 2014, Pages 245-267

  De la Monte, Suzanne M ^a,b  

^a BROWN UNIVERSITY   (United States)

^b Brown University Program in Neurosurgery   (United States)

Author keywords

Alzheimer disease; Cognitive impairment; Diabetes; Insulin resistance; Insulin sensitizers; Neurodegeneration; Obesity

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMYLOID PRECURSOR PROTEIN; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; SOMATOMEDIN B; SOMATOMEDIN C; STREPTOZOCIN;

AGING; ALZHEIMER DISEASE; BRAIN ISCHEMIA; COGNITIVE DEFECT; DIABETES MELLITUS; DIFFUSE LEWY BODY DISEASE; ENDOPLASMIC RETICULUM STRESS; GLUCOSE UTILIZATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; METABOLIC SYNDROME X; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; SIGNAL TRANSDUCTION; BRAIN; CLASSIFICATION; COGNITION DISORDERS; METABOLISM;

AGING; BRAIN; COGNITION DISORDERS; DIABETES MELLITUS; HUMANS; METABOLIC SYNDROME X;

EID: 84896717143     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2013.09.006     Document Type: Review

References (143)

1. Best C.H., Scott D.A. The preparation of insulin. JBiol Chem 1923, 57:709-723.
2. Roth J., Qureshi S., Whitford I., et al. Insulin's discovery: new insights on its ninetieth birthday. Diabetes Metab Res Rev 2012, 28(4):293-304.
3. Gilchrist J.A., Best C.H., Banting F.G. Observations with insulin on Department of Soldiers' Civil Re-Establishment Diabetics. Can Med Assoc J 1923, 13(8):565-572.
4. Gualandi-Signorini A.M., Giorgi G. Insulin formulations-a review. Eur Rev Med Pharmacol Sci 2001, 5(3):73-83.
5. Heinemann L., Richter B. Clinical pharmacology of human insulin. Diabetes Care 1993, 16(Suppl 3):90-100.
6. Dave N., Hazra P., Khedkar A., et al. Process and purification for manufacture of a modified insulin intended for oral delivery. JChromatogr A 2008, 1177(2):282-286.
7. Freiherr J., Hallschmid M., Frey W.H., et al. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 2013, 27(7):505-514.
8. Ott V., Benedict C., Schultes B., et al. Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism. Diabetes Obes Metab 2012, 14(3):214-221.
9. Plum M.B., Sicat B.L., Brokaw D.K. Newer insulin therapies for management of type 1 and type 2 diabetes mellitus. Consult Pharm 2003, 18(5):454-465.
10. Zeyda M., Stulnig T.M. Obesity, inflammation, and insulin resistance-a mini-review. Gerontology 2009, 55(4):379-386.
11. Capeau J. Insulin resistance and steatosis in humans. Diabetes Metab 2008, 34(6 Pt 2):649-657.
12. Dai Z., Wu F., Yeung E.W., et al. IGF-IEc expression, regulation and biological function in different tissues. Growth Horm IGF Res 2010, 20(4):275-281.
13. Matheny R.W., Nindl B.C., Adamo M.L. Minireview: mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology 2010, 151(3):865-875.
14. Kuemmerle J.F. Insulin-like growth factors in the gastrointestinal tract and liver. Endocrinol Metab Clin North Am 2012, 41(2):409-423. vii.
15. de la Monte S.M., Wands J.R. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. JAlzheimers Dis 2005, 7(1):45-61.
16. D'Ercole A.J., Ye P. Expanding the mind: insulin-like growth factor I and brain development. Endocrinology 2008, 149(12):5958-5962.
17. Freude S., Schilbach K., Schubert M. The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. Curr Alzheimer Res 2009, 6(3):213-223.
18. Zeger M., Popken G., Zhang J., et al. Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal invivo oligodendrocyte development and myelination. Glia 2007, 55(4):400-411.
19. de la Monte S.M., Longato L., Tong M., et al. The liver-brain axis of alcohol-mediated neurodegeneration: role of toxic lipids. Int J Environ Res Public Health 2009, 6(7):2055-2075.
20. de la Monte S.M., Longato L., Tong M., et al. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs 2009, 10(10):1049-1060.
21. Gronke S., Clarke D.F., Broughton S., et al. Molecular evolution and functional characterization of Drosophila insulin-like peptides. PLoS Genet 2010, 6(2):e1000857.
22. Shanik M.H., Xu Y., Skrha J., et al. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?. Diabetes Care 2008, 31(Suppl 2):S262-S268.
23. Dankner R., Chetrit A., Shanik M.H., et al. Basal-state hyperinsulinemia in healthy normoglycemic adults is predictive of type 2 diabetes over a 24-year follow-up: a preliminary report. Diabetes Care 2009, 32(8):1464-1466.
24. Garcia R.G., Rincon M.Y., Arenas W.D., et al. Hyperinsulinemia is a predictor of new cardiovascular events in Colombian patients with a first myocardial infarction. Int J Cardiol 2011, 148(1):85-90.
25. Kasai T., Miyauchi K., Kajimoto K., et al. The adverse prognostic significance of the metabolic syndrome with and without hypertension in patients who underwent complete coronary revascularization. JHypertens 2009, 27(5):1017-1024.
26. Agnoli C., Berrino F., Abagnato C.A., et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis 2010, 20(1):41-48.
27. Faulds M.H., Dahlman-Wright K. Metabolic diseases and cancer risk. Curr Opin Oncol 2012, 24(1):58-61.
28. Colonna S.V., Douglas Case L., Lawrence J.A. Aretrospective review of the metabolic syndrome in women diagnosed with breast cancer and correlation with estrogen receptor. Breast Cancer Res Treat 2012, 131(1):325-331.
29. de la Monte S.M., Neusner A., Chu J., et al. Epidemiological trends strongly suggest exposures as etiologic agents in the pathogenesis of sporadic Alzheimer's disease, diabetes mellitus, and non-alcoholic steatohepatitis. JAlzheimers Dis 2009, 17(3):519-529.
30. Cummings J.L. Definitions and diagnostic criteria 2007, Informa UK Limited, London. 3rd edition.
31. Gustaw-Rothenberg K., Lerner A., Bonda D.J., et al. Biomarkers in Alzheimer's disease: past, present and future. Biomark Med 2010, 4(1):15-26.
32. Walsh D.M., Klyubin I., Fadeeva J.V., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation invivo. Nature 2002, 416(6880):535-539.
33. Frolich L., Blum-Degen D., Bernstein H.G., et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. JNeural Transm 1998, 105(4-5):423-438.
34. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 2004, 490(1-3):115-125.
35. Rivera E.J., Goldin A., Fulmer N., et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. JAlzheimers Dis 2005, 8(3):247-268.
36. Steen E., Terry B.M., Rivera E.J., et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. JAlzheimers Dis 2005, 7(1):63-80.
37. de la Monte S.M. Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci (Elite Ed) 2012, E4:1582-1605.
38. de la Monte S.M., Re E., Longato L., et al. Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease. JAlzheimers Dis 2012, 30(0):S217-S229.
39. Caselli R.J., Chen K., Lee W., et al. Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch Neurol 2008, 65(9):1231-1236.
40. Mosconi L., Pupi A., De Leon M.J. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 2008, 1147:180-195.
41. Langbaum J.B., Chen K., Caselli R.J., et al. Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele. Arch Neurol 2010, 67(4):462-468.
42. Hoyer S., Nitsch R. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. JNeural Transm 1989, 75(3):227-232.
43. Hoyer S., Nitsch R., Oesterreich K. Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. JNeural Transm Park Dis Dement Sect 1991, 3(1):1-14.
44. Talbot K., Wang H.Y., Kazi H., et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. JClin Invest 2012, 122(4):1316-1338.
45. Salcedo I., Tweedie D., Li Y., et al. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 2012, 166(5):1586-1599.
46. Piriz J., Muller A., Trejo J.L., et al. IGF-I and the aging mammalian brain. Exp Gerontol 2011, 46(2-3):96-99.
47. Mattson M.P. The impact of dietary energy intake on cognitive aging. Front Aging Neurosci 2010, 2:5.
48. Weinstock M., Shoham S. Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity. JNeural Transm 2004, 111(3):347-366.
49. Lester-Coll N., Rivera E.J., Soscia S.J., et al. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. JAlzheimers Dis 2006, 9(1):13-33.
50. Bolzan A.D., Bianchi M.S. Genotoxicity of streptozotocin. Mutat Res 2002, 512(2-3):121-134.
51. Koulmanda M., Qipo A., Chebrolu S., et al. The effect of low versus high dose of streptozotocin in cynomolgus monkeys (Macaca fascilularis). Am J Transplant 2003, 3(3):267-272.
52. de la Monte S.M., Tong M., Bowling N., et al. si-RNA inhibition of brain insulin or insulin-like growth factor receptors causes developmental cerebellar abnormalities: relevance to fetal alcohol spectrum disorder. Mol Brain 2011, 4:13.
53. Hoyer S. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp Med Biol 2004, 541:135-152.
54. Chen G.J., Xu J., Lahousse S.A., et al. Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. JAlzheimers Dis 2003, 5(3):209-228.
55. Tsukamoto E., Hashimoto Y., Kanekura K., et al. Characterization of the toxic mechanism triggered by Alzheimer's amyloid-beta peptides via p75 neurotrophin receptor in neuronal hybrid cells. JNeurosci Res 2003, 73(5):627-636.
56. de la Monte S.M., Tong M., Lester-Coll N., et al. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. JAlzheimers Dis 2006, 10(1):89-109.
57. Gonzalez-Sanchez J.L., Serrano-Rios M. Molecular basis of insulin action. Drug News Perspect 2007, 20(8):527-531.
58. Etiene D., Kraft J., Ganju N., et al. Cerebrovascular pathology contributes to the heterogeneity of Alzheimer's disease. JAlzheimers Dis 1998, 1(2):119-134.
59. Korf E.S., White L.R., Scheltens P., et al. Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. Diabetes Care 2006, 29(10):2268-2274.
60. de la Monte S.M. Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease. Ann Neurol 1989, 25(5):450-459.
61. Kincaid-Smith P. Hypothesis: obesity and the insulin resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled 'hypertensive nephrosclerosis'. JHypertens 2004, 22(6):1051-1055.
62. Matsumoto H., Nakao T., Okada T., et al. Insulin resistance contributes to obesity-related proteinuria. Intern Med 2005, 44(6):548-553.
63. O'Brien J.T. Role of imaging techniques in the diagnosis of dementia. Br J Radiol 2007, 80(Spec No 2):S71-S77.
64. Poljansky S., Ibach B., Hirschberger B., et al. Avisual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration. Eur Arch Psychiatry Clin Neurosci 2011, 261(6):433-446.
65. Teune L.K., Bartels A.L., de Jong B.M., et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord 2010, 25(14):2395-2404.
66. Nijholt D.A., De Kimpe L., Elfrink H.L., et al. Removing protein aggregates: the role of proteolysis in neurodegeneration. Curr Med Chem 2011, 18(16):2459-2476.
67. Uehara T. Accumulation of misfolded protein through nitrosative stress linked to neurodegenerative disorders. Antioxid Redox Signal 2007, 9(5):597-601.
68. Hol E.M., Fischer D.F., Ovaa H., et al. Ubiquitin proteasome system as a pharmacological target in neurodegeneration. Expert Rev Neurother 2006, 6(9):1337-1347.
69. Kahle P.J., Haass C. How does parkin ligate ubiquitin to Parkinson's disease?. EMBO Rep 2004, 5(7):681-685.
70. Turner B.J., Atkin J.D. ER stress and UPR in familial amyotrophic lateral sclerosis. Curr Mol Med 2006, 6(1):79-86.
71. Morris J.K., Seim N.B., Bomhoff G.L., et al. Effects of unilateral nigrostriatal dopamine depletion on peripheral glucose tolerance and insulin signaling in middle aged rats. Neurosci Lett 2011, 504(3):219-222.
72. Tong M., Dong M., de la Monte S.M. Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. JAlzheimers Dis 2009, 16(3):585-599.
73. Sato N., Takeda S., Uchio-Yamada K., et al. Role of insulin signaling in the interaction between Alzheimer disease and diabetes mellitus: a missing link to therapeutic potential. Curr Aging Sci 2011, 4(2):118-127.
74. Holzenberger M. Igf-I signaling and effects on longevity. Nestle Nutr Workshop Ser Pediatr Program 2011, 68:237-245. [discussion: 246-9].
75. Schuh A.F., Rieder C.M., Rizzi L., et al. Mechanisms of brain aging regulation by insulin: implications for neurodegeneration in late-onset Alzheimer's disease. ISRN Neurol 2011, 2011:306905.
76. Valentini S., Cabreiro F., Ackerman D., et al. Manipulation of invivo iron levels can alter resistance to oxidative stress without affecting ageing in the nematode C. elegans. Mech Ageing Dev 2012, 133(5):282-290.
77. Zemva J., Udelhoven M., Moll L., et al. Neuronal overexpression of insulin receptor substrate 2 leads to increased fat mass, insulin resistance, and glucose intolerance during aging. Age (Dordr) 2012, 35(5):1881-1897.
78. Castilla-Cortazar I., Garcia-Fernandez M., Delgado G., et al. Hepatoprotection and neuroprotection induced by low doses of IGF-II in aging rats. JTransl Med 2011, 9:103.
79. Luque R.M., Lin Q., Cordoba-Chacon J., et al. Metabolic impact of adult-onset, isolated, growth hormone deficiency (AOiGHD) due to destruction of pituitary somatotropes. PloS One 2011, 6(1):e15767.
80. Srikanth V., Westcott B., Forbes J., et al. Methylglyoxal, cognitive function and cerebral atrophy in older people. JGerontol A Biol Sci Med Sci 2012, 68(1):68-73.
81. Williamson R., McNeilly A., Sutherland C. Insulin resistance in the brain: an old-age or new-age problem?. Biochem Pharmacol 2012, 84(6):737-745.
82. Oxenkrug G. Interferon-gamma - inducible inflammation: contribution to aging and aging-associated psychiatric disorders. Aging Dis 2011, 2(6):474-486.
83. Horrillo D., Sierra J., Arribas C., et al. Age-associated development of inflammation in Wistar rats: effects of caloric restriction. Arch Physiol Biochem 2011, 117(3):140-150.
84. Cai D., Liu T. Inflammatory cause of metabolic syndrome via brain stress and NF-kappaB. Aging (Albany NY) 2012, 4(2):98-115.
85. Birk T.J. Poliomyelitis and the post-polio syndrome: exercise capacities and adaptation-current research, future directions, and widespread applicability. Med Sci Sports Exerc 1993, 25(4):466-472.
86. Jubelt B., Cashman N.R. Neurological manifestations of the post-polio syndrome. Crit Rev Neurobiol 1987, 3(3):199-220.
87. Gordon T., Hegedus J., Tam S.L. Adaptive and maladaptive motor axonal sprouting in aging and motoneuron disease. Neurol Res 2004, 26(2):174-185.
88. Dalakas M.C. Pathogenetic mechanisms of post-polio syndrome: morphological, electrophysiological, virological, and immunological correlations. Ann N Y Acad Sci 1995, 753:167-185.
89. Chiang D.J., Pritchard M.T., Nagy L.E. Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2011, 300(5):G697-G702.
90. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34(3):274-285.
91. Lyn-Cook L.E., Lawton M., Tong M., et al. Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. JAlzheimers Dis 2009, 16(4):715-729.
92. de la Monte S.M., Wands J.R. Alzheimer's disease is type 3 diabetes: evidence reviewed. JDiabetes Sci Technol 2008, 2(6):1101-1113.
93. Kraegen E.W., Cooney G.J. Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol 2008, 19(3):235-241.
94. Luchsinger J.A., Reitz C., Patel B., et al. Relation of diabetes to mild cognitive impairment. Arch Neurol 2007, 64(4):570-575.
95. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 2007, 4(2):147-152.
96. Lokken K.L., Boeka A.G., Austin H.M., et al. Evidence of executive dysfunction in extremely obese adolescents: a pilot study. Surg Obes Relat Dis 2009, 5(5):547-552.
97. Gunstad J., Paul R.H., Cohen R.A., et al. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr Psychiatry 2007, 48(1):57-61.
98. Yaffe K. Metabolic syndrome and cognitive decline. Curr Alzheimer Res 2007, 4(2):123-126.
99. Winocur G., Greenwood C.E. Studies of the effects of high fat diets on cognitive function in a rat model. Neurobiol Aging 2005, 26(Suppl 1):46-49.
100. Moroz N., Tong M., Longato L., et al. Limited Alzheimer-type neurodegeneration in experimental obesity and Type 2 diabetes mellitus. JAlzheimers Dis 2008, 15(1):29-44.
101. Baker L.D., Frank L.L., Foster-Schubert K., et al. Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease. JAlzheimers Dis 2010, 22(2):569-579.
102. Baker L.D., Frank L.L., Foster-Schubert K., et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol 2010, 67(1):71-79.
103. Bryan J., Tiggemann M. The effect of weight-loss dieting on cognitive performance and psychological well-being in overweight women. Appetite 2001, 36(2):147-156.
104. Gu Y., Luchsinger J.A., Stern Y., et al. Mediterranean diet, inflammatory and metabolic biomarkers, and risk of Alzheimer's disease. JAlzheimers Dis 2010, 22(2):483-492.
105. Martins I.J., Hone E., Foster J.K., et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 2006, 11(8):721-736.
106. Pasquier F., Boulogne A., Leys D., et al. Diabetes mellitus and dementia. Diabetes Metab 2006, 32(5 Pt 1):403-414.
107. Whitmer R.A. Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep 2007, 7(5):373-380.
108. Crane P.K., Walker R., Hubbard R.A., et al. Glucose levels and risk of dementia. NEngl J Med 2013, 369(6):540-548.
109. Nelson P.T., Smith C.D., Abner E.A., et al. Human cerebral neuropathology of type 2diabetes mellitus. Biochim Biophys Acta 2008, 1792(5):454-469.
110. Janson J., Laedtke T., Parisi J.E., et al. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53(2):474-481.
111. Tong M., Longato L., de la Monte S.M. Early limited nitrosamine exposures exacerbate high fat diet-mediated type2 diabetes and neurodegeneration. BMC Endocr Disord 2010, 10(1):4.
112. Perry W., Hilsabeck R.C., Hassanein T.I. Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci 2008, 53(2):307-321.
113. Weiss J.J., Gorman J.M. Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV. Curr HIV/AIDS Rep 2006, 3(4):176-181.
114. Tong M., Neusner A., Longato L., et al. Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. JAlzheimers Dis 2009, 17(4):827-844.
115. Kao Y., Youson J.H., Holmes J.A., et al. Effects of insulin on lipid metabolism of larvae and metamorphosing landlocked sea lamprey, Petromyzon marinus. Gen Comp Endocrinol 1999, 114(3):405-414.
116. Holland W.L., Summers S.A. Sphingolipids, insulin resistance, and metabolic disease: new insights from invivo manipulation of sphingolipid metabolism. Endocr Rev 2008, 29(4):381-402.
117. Langeveld M., Aerts J.M. Glycosphingolipids and insulin resistance. Prog Lipid Res 2009, 48(3-4):196-205.
118. Kaplowitz N., Than T.A., Shinohara M., et al. Endoplasmic reticulum stress and liver injury. Semin Liver Dis 2007, 27(4):367-377.
119. Malhi H., Gores G.J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28(4):360-369.
120. Sundar-Rajan S., Srinivasan V., Balasubramanyam M., et al. Endoplasmic reticulum (ER) stress & diabetes. Indian J Med Res 2007, 125(3):411-424.
121. Elwing J.E., Lustman P.J., Wang H.L., et al. Depression, anxiety, and nonalcoholic steatohepatitis. Psychosom Med 2006, 68(4):563-569.
122. Felipo V., Urios A., Montesinos E., et al. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab Brain Dis 2011, 27(1):51-58.
123. Schmidt K.S., Gallo J.L., Ferri C., et al. The neuropsychological profile of alcohol-related dementia suggests cortical and subcortical pathology. Dement Geriatr Cogn Disord 2005, 20(5):286-291.
124. Kopelman M.D., Thomson A.D., Guerrini I., et al. The Korsakoff syndrome: clinical aspects, psychology and treatment. Alcohol Alcohol 2009, 44(2):148-154.
125. de la Monte S.M. Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. JAlzheimers Dis 2012, 30:S231-S249.
126. de la Monte S.M., Tong M., Lawton M., et al. Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment. Mol Neurodegener 2009, 4:54.
127. de la Monte S.M., Tong M., Nguyen V., et al. Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. JAlzheimers Dis 2010, 21(3):967-984.
128. Tong M., de la Monte S.M. Mechanisms of ceramide-mediated neurodegeneration. JAlzheimers Dis 2009, 16(4):705-714.
129. Alessenko A.V., Bugrova A.E., Dudnik L.B. Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer's disease. Biochem Soc Trans 2004, 32(Pt 1):144-146.
130. Adibhatla R.M., Hatcher J.F. Altered lipid metabolism in brain injury and disorders. Subcell Biochem 2008, 49:241-268.
131. Kassi E., Pervanidou P., Kaltsas G., et al. Metabolic syndrome: definitions and controversies. BMC Med 2011, 9:48.
132. Tan Z.S., Beiser A.S., Fox C.S., et al. Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: the Framingham Offspring Study. Diabetes Care 2011, 34(8):1766-1770.
133. Debette S., Beiser A., Hoffmann U., et al. Visceral fat is associated with lower brain volume in healthy middle-aged adults. Ann Neurol 2010, 68(2):136-144.
134. Hassenstab J.J., Sweat V., Bruehl H., et al. Metabolic syndrome is associated with learning and recall impairment in middle age. Dement Geriatr Cogn Disord 2010, 29(4):356-362.
135. Frisardi V., Solfrizzi V., Capurso C., et al. Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome?. JAlzheimers Dis 2010, 21(1):57-63.
136. Yates K.F., Sweat V., Yau P.L., et al. Impact of metabolic syndrome on cognition and brain: a selected review of the literature. Arterioscler Thromb Vasc Biol 2012, 32(9):2060-2067.
137. Burns J.M., Honea R.A., Vidoni E.D., et al. Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging. Biochim Biophys Acta 2012, 1822(3):333-339.
138. Benedict C., Hallschmid M., Schmitz K., et al. Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 2007, 32(1):239-243.
139. Craft S., Baker L.D., Montine T.J., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2011, 69(1):29-38.
140. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat CNS Drug Discov 2010, 5(2):109-117.
141. Krikorian R., Eliassen J.C., Boespflug E.L., et al. Improved cognitive-cerebral function in older adults with chromium supplementation. Nutr Neurosci 2010, 13(3):116-122.
142. Reger M.A., Watson G.S., Green P.S., et al. Intranasal insulin improves cognition and modulates {beta}-amyloid in early AD. Neurology 2008, 70(6):440-448.
143. Luchsinger J.A. Type 2 diabetes, related conditions, in relation and dementia: an opportunity for prevention?. JAlzheimers Dis 2010, 20(3):723-736.